Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. It also provides generic and branded formulations in the therapeutic segments, including cardiology, gastroenterology, dermatology, rheumatology, urology, ophthalmology, infectious disease, immunosuppressant, probiotics, respiratory, allergy, nutraceuticals, anti-neoplastic, malarial, neurology, psychiatry, orthopedics, helminthics, fever, hematology, hepatoprotective, diabetology, anti-epileptic, emollients/protectives, NSAIDs, rheumatology, anti-arthritic, and neuropathic pain, as well as products in various dosage forms comprising oral solids, powders for suspension, and liquid and dry injections. The company exports its products to approximately 100 countries worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

NSE:IPCALAB

Ipca Laboratories Limited

₹

Last Close

900.05

22/09 10:00

Market Cap

218.67B

Beta: 0.09

Volume Today

474.02K

Avg: 245.58K

PE Ratio

39.30

PEG: -1.75

Dividend Yield

0.49%

Payout:19.33%

Please Sign In To Use The Chat